# Hui-Gene Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hui-gene-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.huidagene.com
- Total disclosed funding: $4.3M
- Latest round: Series C (May 12, 2022)
- Investors on record: 6

## About

Based in Shanghai, China and established in 2018, Hui-Gene Therapeutics is a biotechnology company that focuses on gene research, gene editing technology, and gene therapy solutions. The company has 5500 square meter research laboratory, about 10 development pipeline and 200 staffs in R&D team. The founders Linyu Shi and Xuanyao are doctors from Developmental biology and Department of neurology of Chinese Academy respectively. The company has raised RMB 400 million in series B funding and has raised 3 round funding since it established.

The company is an innovative biopharmaceutical company focusing on gene editing technology and gene therapy drug development. It focuses on RNA gene editing technology and gene therapy preclinical research and development platform, its pipeline covers neurodegenerative diseases, visual disorders, hearing disorders and other diseases.

The company will put the funding towards technology and pipeline R&D, product registration application, team and production base construction in series C funding.

## Funding rounds

- Series C, May 12, 2022 — CD Capital, Shanhai Capital, Sherpa Healthcare Partners
- Series A, Dec 2, 2019 — CD Capital, Alwin Capital, Sherpa Healthcare Partners, HM Healthcare Management Services, Wuxi AppTec Group
- Angel, Nov 1, 2018, $4.3M — Sherpa Healthcare Partners

## Investors

- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Angel, Series A, Series C
- CD Capital — Series A, Series C
- Alwin Capital — Series A
- HM Healthcare Management Services — Series A
- Wuxi AppTec Group — Series A
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series C